|Bid||0.0000 x 1300|
|Ask||0.0000 x 800|
|Day's Range||2.2600 - 2.4200|
|52 Week Range||2.2600 - 5.3900|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2021 - Nov 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
Subscribe to Yahoo Finance Plus to view Fair Value for ACERLearn more
Key ACER-001 formulation composition of matter patent strengthens proprietary position in U.S. until 2036NEWTON, Mass. and GENEVA, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new U.S. patent to Acer for certain claims related to ACER-001 (sodium phenylbutyrate). Patent 11
Acer Therapeutics Inc. ( NASDAQ:ACER ) is possibly approaching a major achievement in its business, so we would like to...
The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022. Stock up.